These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11505177)

  • 1. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study.
    Gaist D; Rodríguez LA; Huerta C; Hallas J; Sindrup SH
    Epidemiology; 2001 Sep; 12(5):565-9. PubMed ID: 11505177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?
    Gaist D; García Rodríguez LA; Huerta C; Hallas J; Sindrup SH
    Eur J Clin Pharmacol; 2001 Mar; 56(12):931-3. PubMed ID: 11317483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
    Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
    Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Unnoticed hypothyroidism and myopathy due to lipid-lowering drugs].
    Gascón Ramón G; Bertomeu Blanch F; Meneu Montoliu V; Fenollosa Tamarit MD
    Aten Primaria; 2001 Apr; 27(6):442-3. PubMed ID: 11334586
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myopathy and rhabdomyolysis with lipid-lowering drugs.
    Hodel C
    Toxicol Lett; 2002 Mar; 128(1-3):159-68. PubMed ID: 11869826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myopathy due to statin/fibrate use in the Netherlands.
    Mantel-Teeuwisse AK; Klungel OH; Herings RM; van Puijenbroek EP; Porsius AJ; de Boer A
    Ann Pharmacother; 2002 Dec; 36(12):1957-60. PubMed ID: 12452761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and the risk of dementia.
    Jick H; Zornberg GL; Jick SS; Seshadri S; Drachman DA
    Lancet; 2000 Nov; 356(9242):1627-31. PubMed ID: 11089820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibitors and the risk of fractures.
    Meier CR; Schlienger RG; Kraenzlin ME; Schlegel B; Jick H
    JAMA; 2000 Jun; 283(24):3205-10. PubMed ID: 10866867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
    Corrao G; Zambon A; Bertù L; Botteri E; Leoni O; Contiero P
    J Epidemiol Community Health; 2004 Dec; 58(12):1047-51. PubMed ID: 15547071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.
    Hanna IR; Heeke B; Bush H; Brosius L; King-Hageman D; Dudley SC; Beshai JF; Langberg JJ
    Heart Rhythm; 2006 Aug; 3(8):881-6. PubMed ID: 16876733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents].
    Franc S; Bruckert E; Giral P; Turpin G
    Presse Med; 1997 Dec; 26(38):1855-8. PubMed ID: 9569908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk for myopathy with statin therapy in high-risk patients.
    Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
    Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk among statin users: a population-based cohort study.
    Friis S; Poulsen AH; Johnsen SP; McLaughlin JK; Fryzek JP; Dalton SO; Sørensen HT; Olsen JH
    Int J Cancer; 2005 Apr; 114(4):643-7. PubMed ID: 15578694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?
    Mantel-Teeuwisse AK; Klungel OH; Verschuren WM; Porsius AJ; de Boer A
    Br J Clin Pharmacol; 2002 Apr; 53(4):379-85. PubMed ID: 11966669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering agents and myopathy.
    Wortmann RL
    Curr Opin Rheumatol; 2002 Nov; 14(6):643-7. PubMed ID: 12410084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.